AbCellera Q2 net loss widens on higher expenses - ABCL News | RalliesAbCellera Q2 net loss widens on higher expenses
A
ABCL• Outlook
- Company expects top-line data from ABCL635 Phase 2 trial in August 2026
- Top-line data from ABCL575 Phase 1 study expected in Q4 2026
- AbCellera to receive over $100 mln in upfront cash from recent collaborations
Overview
- US biotechnology firm's Q2 revenue declined and missed analyst expectations
- Net loss widened to $55.4 mln from $34.7 mln a year earlier
- Company signed new collaborations with Jazz and Vertex, adding over $100 mln upfront cash
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Revenue | Miss | $4.1 mln | $7.78 mln (7 Analysts) |
| Q2 Net Loss | | $55.4 mln | |
Result drivers
- R&D spending - Co said higher research and development expenses contributed to wider net loss
- New collaborations - Co signed deals with Jazz and Vertex, adding over $100 mln in upfront cash
•
